Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592015 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
A Phase 2 study of T-cell Large Granular Lymphocyte Leukemia, sponsored by Jonathan Brammer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05592015 is a Phase 2 study of T-cell Large Granular Lymphocyte Leukemia that is actively recruiting participants, run by Jonathan Brammer. The registered enrollment target is 30 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT05592015, a Phase 2 study of T-cell Large Granular Lymphocyte Leukemia, is actively recruiting participants, sponsored by Jonathan Brammer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (3)
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05592015
The ClinicalTrials.gov registry entry for NCT05592015 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonathan Brammer, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T-cell Large Granular Lymphocyte Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT05592015 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05592015 about?
NCT05592015 is a clinical study titled "Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia". This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT05592015?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-05-03. Estimated completion is 2026-07-31.
What conditions does trial NCT05592015 study?
This clinical trial studies the following conditions: T-cell Large Granular Lymphocyte Leukemia.
What interventions are being tested in trial NCT05592015?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT05592015?
This trial is sponsored by Jonathan Brammer, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05592015 being conducted?
This trial has 3 study locations across Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Large Granular Lymphocyte Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.